Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.30 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL772272 | 1.00 | ACHE (0.37) | ACHEMGLLLTA4HRECQLALDH1A1 | |
| SCHEMBL1786983 | 0.88 | — | — | |
| SCHEMBL2005669 | 0.79 | LTA4H (0.38) | ACHEMGLLLTA4HHRH3HRH2 | |
| SCHEMBL3543013 | 0.74 | ACHE (0.39) | ACHEMGLLLTA4HRECQLALDH1A1 | |
| SCHEMBL6902050 | 0.74 | ACHE (0.39) | ACHEMGLLLTA4HRECQLALDH1A1 | |
| SCHEMBL13407651 | 0.74 | ACHE (0.39) | ACHEMGLLLTA4HRECQLALDH1A1 | |
| SCHEMBL23828674 | 0.72 | HRH3 (0.44) | LTA4HHRH3HRH2HRH1MAOB | |
| SCHEMBL2058182 | 0.72 | MGLL (0.39) | ACHEMGLLLTA4HRECQLALDH1A1 | |
| SCHEMBL17706248 | 0.72 | ACHE (0.37) | ACHEMGLLLTA4HRECQLALDH1A1 | |
| SCHEMBL14125682 | 0.72 | ACHE (0.37) | ACHEMGLLLTA4HRECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0071216-B1 | 3-HYDROXYPYRROLIDIN-2-ONE DERIVATIVES, PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-12-30 | — | — | EP | claimed |
| US-4476308-A | 1-Pyrrolidine acetamides | HOFFMANN-LA ROCHE INC. (US) | 1984-10-09 | — | — | US | claimed |
| EP-0050589-B1 | PHARMACEUTICAL COMPOSITIONS WITH AN ANTI-EPILEPTIC AND ANTI-NEURALGIC EFFECT, AND PROCESS FOR THEIR MANUFACTURE | CIBA-GEIGY AG (CH) | 1984-09-12 | — | — | EP | claimed |
| EP-0071216-A2 | 3-Hydroxypyrrolidin-2-one derivatives, process and intermediates for their preparation and pharmaceutical preparations containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-02-09 | — | — | EP | claimed |
| EP-0050589-A1 | Pharmaceutical compositions with an anti-epileptic and anti-neuralgic effect, and process for their manufacture | CIBA-GEIGY AG (CH) | 1982-04-28 | — | — | EP | claimed |
| US-4104380-A | Dibenzyl glycolic acid derivatives | WARNER-LAMBERT COMPANY (US) | 1978-08-01 | — | — | US | claimed |
| US-4076937-A | Dibenzyl glycolic acid derivatives | WARNER-LAMBERT COMPANY (US) | 1978-02-28 | — | — | US | claimed |
| US-20230364053-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER | TOKYO METROPOLITAN GERIATRIC HOSPITAL AND INSTITUTE OF GERONTOLOGY (JP) | 2023-11-16 | — | — | US | disclosed |
| EP-4223293-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER | Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology (JP) | 2023-08-09 | — | — | EP | disclosed |
| US-10959432-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2021-03-30 | — | — | US | disclosed |
| US-10757941-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-09-01 | — | — | US | disclosed |
| US-20200267986-A1 | Microbiocidal Oxadiazole Derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-08-27 | — | — | US | disclosed |
| US-10687533-B2 | Microbiocidal oxadiazole derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2020-06-23 | — | — | US | disclosed |
| EP-0192255-A2 | Bis-2H-pyrrolidine diones | CIBA-GEIGY AG (CH) | 1986-08-27 | — | — | EP | disclosed |
| US-4476308-A | 1-Pyrrolidine acetamides | HOFFMANN-LA ROCHE INC. (US) | 1984-10-09 | — | — | US | disclosed |
| EP-0050589-B1 | PHARMACEUTICAL COMPOSITIONS WITH AN ANTI-EPILEPTIC AND ANTI-NEURALGIC EFFECT, AND PROCESS FOR THEIR MANUFACTURE | CIBA-GEIGY AG (CH) | 1984-09-12 | — | — | EP | disclosed |
| US-4431641-A | AN ANTICONVULSANT DIBENZ/B,F/AZEPINE POTENTIATED BY A VINCAMINE OR PIRACETAM DERIVATIVE | CIBA-GEIGY CORPORATION (US) | 1984-02-14 | — | — | US | disclosed |
| EP-0071216-A2 | 3-Hydroxypyrrolidin-2-one derivatives, process and intermediates for their preparation and pharmaceutical preparations containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-02-09 | — | — | EP | disclosed |
| EP-0050589-A1 | Pharmaceutical compositions with an anti-epileptic and anti-neuralgic effect, and process for their manufacture | CIBA-GEIGY AG (CH) | 1982-04-28 | — | — | EP | disclosed |
| EP-0050589-A1 | Pharmaceutical compositions with an anti-epileptic and anti-neuralgic effect, and process for their manufacture | CIBA-GEIGY AG (CH) | 1982-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10959432-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | ACHE 832/4885MGLL 106/4885LTA4H 427/4885 |
| US-10687533-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | ACHE 832/4885MGLL 106/4885LTA4H 427/4885 |
| US-10757941-B2 | Microbiocidal oxadiazole derivatives | PRF1, NOX1, ARG1 | ACHE 816/4885MGLL 109/4885LTA4H 457/4885 |
| US-20230364053-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PROSTATE CANCER OR BREAST CANCER | AR, NR5A1, CYP17A1 | ACHE 3613/4885MGLL 3684/4885LTA4H 2477/4885 |
| US-20200267986-A1 | Microbiocidal Oxadiazole Derivatives | PRF1, NOX1, ARG1 | ACHE 832/4885MGLL 106/4885LTA4H 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.